Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CLINICAL EFFICACY AND PECULIARITY OF COMPLIANCE WITH 48-WEEK LONG THERAPY WITH EGILOK RETARD IN PATIENTS WITH MILD TO MODERATE HYPERTENSION

https://doi.org/10.20996/1819-6446-2006-2-2-25-31

Full Text:

Abstract

Aim. To study antihypertensive efficacy of long-acting metoprolol, its influence on heart rate variability and therapy compliance in hypertensive patients during long-term (48 weeks) treatment. Material and Methods. After 2 weeks of wash-out period 30 hypertensive patients were prescribed long-acting metoprolol (Egilok Retard, EGIS) in dose of 50-100 mg once daily. If necessary the dose was increased up to 200 mg daily on 2 or 8 week, and on 12-16 weeks hydrochlorothiazide 12,5-25 mg daily and then nifedipine 20 mg daily were added. Ambulatory blood pressure monitoring (ABPM) and daily ECG monitoring were applied on 24 and 48 weeks. Patient quality of life was estimated. Results. In 48 weeks 22 patients (73,3%) continued the treatment. 5 patients dropped out because of low compliance and 3 patients because of low efficacy. Therapy discontinuation because of side effects was necessary in no one case. Monotherapy with metoprolol provided excellent results in 15 (68%) and combined therapy - in 7 (32%) patients. In comparison with starting data on 48 week of treatment significant reduction in 24-hour , day and night systolic blood pressure (BP) was registered on 10,4±1,6; 11,3±1,7 and 5,2±1,9 mm Hg, respectively, as well as diastolic BP on 7,7±1,1; 8,1±1,3 and 4,1±1,3 mm Hg, respectively. Time index of hypertension for 24-hour systolic and diastolic BP decreased significantly. Daily BP profile normalized. Normalization of BP and heart rate variability was observed among patients with its initial disturbances. The frequency of hypertensive symptoms such as headache and dizziness reduced on 58% and 64%, respectively. Capacity for work improved significantly. Conclusion. Long-acting metoprolol is effective antihypertensive medicine providing high level of compliance with long-term therapy.  Long-acting metoprolol is especially indicated to hypertensive patients with sympathetic system overactivity.

About the Authors

V. E. Oleynikov
Penza Medical Institute
Russian Federation


V. A. Budanova
Penza Medical Institute
Russian Federation


A. V. Kulucin
Penza Medical Institute
Russian Federation


References

1. Wood D, De Bcker G, Faergeman O, et al. For the Second Joint Task Force of European and other Societiest on Coronary Prevention: European an Society, European Society of hypertension, Internation Society of Behavioural Medicine, European Societyn of General Practice family Medicine, European Network. Prevention of coronary heart disease in clinical practice.Eur Heart J 1998;19:1434-1503.

2. World Health Organisation (2003): Adherence to long – term therapies, evidens for action.- Geneva.

3. Гуревич К.Г. Комплаенс больных, получающих гипотензивную терапию. Качественная клиническая практика 2003; 4:53-58

4. Белоусов Ю.Б., Шляхто Е.В, Леонова М.В. и др. Окончательные результаты фармакоэпидемиологического исследования больных артериальной гипертонией в РФ от имени аналитической группы исследования ПИФАГОР. Артериальная гипертензия. 2004. Т.10. 4:185-193

5. Шляхто Е.В. Патогенез гипертонической болезни (эссенциальной гипертонии). Руководство по артериальной гипертонии под ред. акад. Е.И. Чазова, проф. И.Е.Чазовой. – М.: Медиа Меди- ка,2005:41-61

6. Yulius S, Krause L, Schork N et al. Hyperkinetik borderline hypertension in Tecumseb, Michigan.Y Hypertens 1991; 9:77-84.

7. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. Суточное мониторирование артериального давления при гипертонии. М: Медицина, 1998:45

8. Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериально- го давления: методические аспекты и клиническое значение. М; 1999:234.

9. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония 2000: ключевые аспекты диагностики и дифференциальной диагностики, профилактики, клиник и лечения. Под ред. чл-корр РАМН В.С. Моисеева М. 2001:208

10. Ольбинская Л.И., Мартынов А.И., Хапаев Б.А. Мониторирование артериального давления в кардиологии: М; 1998:56.

11. Олейников В.Э., Буданова В.А., Кулюцин А.В., Белоусов Ю.Б. Эффективность Эгилока ретард и его влияние на вариабельность сердечного ритма при мягкой и умеренной артериальной гипертензии. Фарматека. 2005:20(115):113-118.

12. Bigger J.T. Jr. The electrical activity of the heart. In: “Hurst?s the heart” 8-th ed. 1994

13. Арабидзе Г.Г., Белоусов Ю.Б., Карпов Ю.А. Артериальная гипертония. Справочное руководство по диагностике и лечению. – М. -1999.

14. Явелов И.С., Грацианский Н.А., Зуйков Ю.А. Вариабельность ритма сердца при острых коронарных синдромах: значение для оценки прогноза заболевания (ч 1).Кардиология 1997; 2: 61- 67

15. Akselrod S. Components of heart rate variability: basic studies. From: Malik M., Gamm AJ (eds.): Heart rate variability. Armonk, NY. Future Publishing Compani, Inc., 1995: 147-160.

16. Task force of the European Society of Cardiology and the North American Society of pacing and electrophysiology. Heart rate variability. Standarts of measurement, physiological interpretation and clinicaluse.Eur Heart J 1996; 17: 354-381

17. Cohen J.S.Arch Jntern Med 2001; 161 (6): 880-5

18. Хохлов А.Л., Лисенкова Л.А., Раков А.А. Анализ факторов, определяющих приверженность к антигипертензивной терапии. Качественная клиническая практика 2003:4: 59-66.


For citation:


Oleynikov V.E., Budanova V.A., Kulucin A.V. CLINICAL EFFICACY AND PECULIARITY OF COMPLIANCE WITH 48-WEEK LONG THERAPY WITH EGILOK RETARD IN PATIENTS WITH MILD TO MODERATE HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2006;2(2):25-31. (In Russ.) https://doi.org/10.20996/1819-6446-2006-2-2-25-31

Views: 303


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)